Compare Citius Pharmaceuticals Inc (CTXR) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Centrus Energy Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Centrus Energy Corp trades at $142.44 (market cap $2.91B). The key difference: Centrus Energy Corp is far larger — about 213.7× Citius Pharmaceuticals Inc's market cap, and Centrus Energy Corp is more actively traded (903,777 versus 132,438). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Centrus Energy Corp for 29 Days on average.
| CTXR | LEU | |
|---|---|---|
Market Cap | $13.62M | $2.91B |
Volume | 132,438 | 903,777 |
Sector | Health | Energy |
52-Week High | $1.82 | $436.00 |
52-Week Low | $0.48 | $138.18 |
Typical Hold Time | 17 Days | 29 Days |
Enterprise Value | $3.79M | $2.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Centrus Energy (LEU) trades at $142.09, down 3.43% on the day, with technical indicators showing a bearish trend. The company reported mixed quarterly results, missing Q4 2025 EPS estimates but beating in Q1 and Q2 2026. Recent news highlights Centrus as a key player in the nuclear fuel supply chain, securing multiple HALEU contracts amid growing nuclear energy demand. Valuation metrics appear elevated with a P/E of 75.18 and P/S of 6.68, while profitability metrics show a net income margin of 10.23% and ROE of 8.05%.
The outlook for LEU is cautiously optimistic, supported by strategic positioning in the nuclear fuel market and recent contract wins. However, high valuation multiples and recent earnings volatility present risks. Analyst consensus is mixed with 46% buy ratings and a $218.10 price target, suggesting potential upside if execution improves. Key risks include execution challenges, competitive pressures, and dependence on nuclear energy policy support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
